Ascletis Pharma Inc.
ASCLF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $57 | $54 | $77 |
| % Growth | -97.7% | 4.6% | -29.6% | – |
| Cost of Goods Sold | $1 | $31 | $79 | $38 |
| Gross Profit | $1 | $26 | -$25 | $39 |
| % Margin | 57.3% | 45.9% | -45.6% | 51% |
| R&D Expenses | $302 | $217 | $267 | $213 |
| G&A Expenses | $102 | $63 | $15 | $16 |
| SG&A Expenses | $102 | $63 | $32 | $37 |
| Sales & Mktg Exp. | $0 | $0 | $17 | $21 |
| Other Operating Expenses | -$108 | $46 | $20 | $13 |
| Operating Expenses | $296 | $326 | $319 | $264 |
| Operating Income | -$295 | -$300 | -$344 | -$225 |
| % Margin | -23,025.6% | -530.4% | -635.9% | -292.6% |
| Other Income/Exp. Net | -$6 | $155 | $29 | $26 |
| Pre-Tax Income | -$301 | -$145 | -$315 | -$199 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$301 | -$145 | -$315 | -$199 |
| % Margin | -23,455.7% | -255.7% | -582.1% | -258.9% |
| EPS | -0.3 | -0.13 | -0.29 | -0.18 |
| % Growth | -130.8% | 55.2% | -61.1% | – |
| EPS Diluted | -0.3 | -0.13 | -0.29 | -0.18 |
| Weighted Avg Shares Out | 1,002 | 1,074 | 1,087 | 1,098 |
| Weighted Avg Shares Out Dil | 1,002 | 1,074 | 1,087 | 1,098 |
| Supplemental Information | – | – | – | – |
| Interest Income | $92 | $99 | $44 | $23 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $14 | $18 | $30 | $30 |
| EBITDA | -$390 | -$126 | -$284 | -$169 |
| % Margin | -30,432.6% | -222.8% | -526% | -220.3% |